This article comes from references available on internet. It is about a new drug called Glucagon-like Peptide-1 [GLP-1] Receptor Agonists.
So GLP-1R Agonists is analog of human glucagon-like peptide-1, and it acts as GLP-1 receptor agonist to increase insulin secretion in the presence of elevated blood glucose. Also it delays gastric emptying to decrease postprandial glucose and decreases glucagon secretion.
So what is Glucagon-like Peptide-1 [GLP-1]?
GLP-1 is one kind of native human hormones called Incretins, which is produced by the proglucagon gene in L-cells of the small intestine. GLP-1 decreases and control blood glucose by various mechanism including: .Liver: reduces hepatic glucose output by inhibiting glucagon release. . Alpha cell: inhibits glucagon secretion. .CNS: promotes satiety. .Stomach: slows gastric emptying. .Beta cell: stimulates glucose-dependent insulin secretion and beta-cell differentiation and proliferation.
Thus, modulating GLP-1 levels and GLP-1 activity through administration of the native hormone, analogs, and mimetics or by inhibiting its degradation has become a major focus of investigation for treating type 2 diabetes over the past decade.
Another important thing, where can we find the receptor of GLP-1?
The receptor is found on pancreatic periductal cells and β-cells and in the kidney, heart, stomach, and brain. GLP-1 receptor (GLP-1R) knockout mice have fasting hyperglycemia and abnormal glucose tolerance but are not obese.
.Medscape: Guideline Discusses Oral Pharmacotherapy for Type 2 Diabetes. Full reference: http://www.medscape.org/viewarticle/758426?src=cmemp
.Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide. Full reference: http://clinical.diabetesjournals.org/content/23/2/56.full
.Glucagon-Like Peptide-1 Receptor Agonists Promote Weight Loss. Full reference: http://www.medscape.org/viewarticle/757036